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May-Hegglin anomaly (MHA) and Fechtner (FTNS) and Sebastian (SBS) syndromes are autosomal dominant platelet
disorders that share macrothrombocytopenia and characteristic leukocyte inclusions. FTNS has the additional
clinical features of nephritis, deafness, and cataracts. Previously, mutations in the nonmuscle myosin heavy chain
9 gene (MYH9), which encodes nonmuscle myosin heavy chain IIA (MYHIIA), were identified in all three disorders.
The spectrum of mutations and the genotype-phenotype and structure-function relationships in a large cohort of
affected individuals ( ) has now been examined. Moreover, it is demonstrated that MYH9 mutations alsonp 27
result in two other FTNS-like macrothrombocytopenia syndromes: Epstein syndrome (EPS) and Alport syndrome
with macrothrombocytopenia (APSM). In all five disorders, MYH9 mutations were identified in 20/27 (74%)
affected individuals. Four mutations, R702C, D1424N, E1841K, and R1933X, were most frequent. R702C and
R702H mutations were only associated with FTNS, EPS, or APSM, thus defining a region of MYHIIA critical in
the combined pathogenesis of macrothrombocytopenia, nephritis, and deafness. The E1841K, D1424N, and
R1933X coiled-coil domain mutations were common to both MHA and FTNS. Haplotype analysis using three
novel microsatellite markers revealed that three E1841K carriers—one with MHA and two with FTNS—shared a
common haplotype around theMYH9 gene, suggesting a common ancestor. The two new globular-head mutations,
K371N and R702H, as well as the recently identified MYH9 mutation, R705H, which results in DFNA17, were
modeled on the basis of X-ray crystallographic data. Altogether, our data suggest that MHA, SBS, FTNS, EPS,
and APSM comprise a phenotypic spectrum of disorders, all caused by MYH9 mutations. On the basis of our
genetic analyses, the name “MYHIIA syndrome” is proposed to encompass all of these disorders.
Introduction
Inherited giant-platelet disorders represent a group of
rare disorders characterized by thrombocytopenia, large
platelets, and variable bleeding symptoms (Mhawech
and Saleem 2000). Given lack of reporting and misdi-
agnosis, the real prevalences of these disorders are most
likely underestimated. The autosomal dominant disor-
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ders May-Hegglin anomaly (MHA [MIM 155100]; May
1909; Hegglin 1945), Fechtner syndrome (FTNS [MIM
153640]; Peterson et al. 1985), and Sebastian syndrome
(SBS [MIM 605249]; Greinacher et al. 1990b) share the
triad of thrombocytopenia, large platelets, and charac-
teristic leukocyte inclusions (Do¨hle-like bodies) (table 1).
MHA and SBS are differentiated by ultrastructural ex-
amination of leukocyte inclusions. These paracrystalline
inclusions appear as highly parallel bodies in MHA but
are smaller and less organized in SBS and FTNS. FTNS
is distinguished by the additional clinical features of
high-tone sensorineural deafness, cataracts, and nephri-
tis (Peterson et al. 1985) (table 1). Two other FTNS-like
macrothrombocytopenias of unknown genetic etiology
have also been described. The first is a subset of auto-
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Table 1
Clinical and Morphological Features of the Five Autosomal
Dominant Macrothrombocytopenias, MHA, SBS, FTNS, EPS, and
APSM
DISORDER
CLINICAL FEATUREa
MTCP
Leukocyte
Inclusions Nephritis
High-Tone
Sensorineural
Deafness Cataracts
MHA     
SBS     
EPS     
FTNS     
APSM     
a  p present;  p absent.
somal dominant Alport syndrome (APS), but with plate-
let defects (APSM [MIM 153650]; Atkin et al. 1986)
(table 1). The classic form of APS is an X-linked disorder
of the glomerular basement membranes and is charac-
terized by progressive renal failure, deafness, and ocular
lesions (MIM 301050; Alport 1927). This form results
from mutations in the COL4A5 gene, which encodes
the type IV a-5 collagen chain (Barker et al. 1990).
COL4A5 mutations have not been found in APSM-af-
fected individuals. The second macrothrombocytopenia
is Epstein syndrome (EPS [MIM 153650]), which has
clinical similarities to FTNS and APSM, although cat-
aracts and leukocyte inclusions have not been described
(Epstein et al. 1972) (table 1).
Linkage-analysis studies in families with MHA,
FTNS, SBS, and EPS had previously been performed
and had localized the disease gene to chromosome
22q11-13 in all disorders (Martignetti et al. 2000; Toren
et al. 2000). Subsequently, mutations in the nonmuscle
myosin heavy chain 9 gene (MYH9), which lies in this
region, were demonstrated in all three disorders: MHA,
FTNS, and SBS (May-Hegglin/Fechtner Syndrome Con-
sortium 2000). It has also been shown that a specific
missense mutation in MYH9, R705H, results in non-
syndromic deafness, DFNA17, an autosomal dominant
high-tone sensorineural deafness without platelet ab-
normalities (Lalwani et al. 2000).
MYH9 encodes nonmuscle myosin IIA (MYHIIA),
which is expressed in many different tissues, includ-
ing platelets, kidney (Simons et al. 1991), leukocytes
(Toothaker et al. 1991), and cochlea (Lalwani et al.
2000). Myosins constitute a diverse superfamily, with,
to date, 18 different classes. MYHIIA is classified as a
class II conventional myosin. These are hexameric en-
zymes composed of two heavy chains and two pairs of
light chains. Dimerization of two heavy chains results
in a polar structure with two distinct regions. The amino
terminus forms a globular head that binds to actin and
ATP, has ATPase activity, and is required for motor
activity. The C-terminal a-helical coiled-coil domain
comprises the regulatory region (Harrington and Rod-
gers 1984). Interestingly, mutations in three unconven-
tional myosins have previously been associated with
deafness and inner ear hair-cell dysfunction, which is
present in FTNS, EPS, and APSM. Mutations in the
myosin VIIA gene can result in the Usher syndrome type
IB (congenital deafness, vestibular areflexia, and pro-
gressive retinitis pigmentosa; Weil et al. 1995) and in
recessive nonsyndromic deafness DFNB2 (Liu et al.
1997; Weil et al. 1997). DFNB3 is caused by mutations
in the myosin XV gene (Wang et al. 1998). Finally,
mutations in the myosin VI gene have been found to
result in “Snell’s waltzer” deafness in mice (Avraham
et al. 1995) and, most recently, in a nonsyndromic form
of postlingual human deafness, DFNA22 (Melchionda
et al. 2001).
In the present study, we performed molecular analyses
of 27 previously unstudied families with MHA, SBS,
FTNS, EPS, and APSM, defined the common genetic
etiology of these five autosomal dominant macrothrom-
bocytopenias, and analyzed structure-function and ge-
notype-phenotype characteristics of detected MYH9
mutations. Our results, combined with the mutation
data of previous studies (Kelley et al. 2000; Lalwani et
al. 2000; May-Hegglin/Fechtner Syndrome Consortium
2000 Kunishima et al. 2001), suggest that all six syn-
dromes represent one class of disorder with phenotypic
variability. Therefore, the name “MYHIIA syndrome”
is proposed to encompass these disorders.
Subjects and Methods
Individuals and Families
After informed consent and institutional review board
approval from the corresponding institutions were ob-
tained, blood samples were obtained from 27 individuals
with diagnoses of MHA, SBS, FTNS, EPS, and APSM
(table 2) and, where possible, from relevant family mem-
bers. Clinical diagnoses were provided by referring phy-
sicians. Urinalysis, ophthalmologic examination, and
hearing tests were performed to determine the clinical
features of affected individuals. Leukocyte inclusions
were characterized by electron microscopy. Genomic
DNA was isolated from whole blood (Nicolaides and
Stoeckert 1990).
Mutation Analysis
Primers were designed to amplify all 40 coding exons
(exons 1–40), their intron/exon boundaries, and reg-
ulatory regions (Kawamoto 1994; Beohar and Kawa-
moto 1998; human MYH9 GenBank accession number
3135984) (fig. 1 and table 2). PCR amplifications were
performed in a 25-ml volume with 10 ng of genomic
DNA, 20 mM of each primer, 200 mM dNTPs, 10 mM
Table 2
Clinical and Morphological Features of 27 Individuals with a Diagnosis of MHA, FTNS, SBS, EPS, or APSM
PATIENT ID
NUMBER DISORDERa
ETHNIC ORIGIN AND
COUNTRY OF ORIGIN
FAMILIAL OR
SPORADIC
CLINICAL FEATUREb
REFERENCE FOR CLINICAL DETAILScMTCP Do¨hle-like bodies Nephritis Deafness Cataracts
1 SBS European, Germany Familial      Greinacher et al. 1990a
2 SBS European, Germany Familial      Toren et al. 2000
3 FTNS European, Germany ND      …
4 SBS European, Germany Familial      …
5 MHA/SBS European, Germany Familial      …
6 FTNS European, U.S.A. Familial      …
7 FTNS African American, U.S.A. Familial  ND    …
8 MHA European, U.S.A. ND      …
9 FTNS European, U.S.A. Familial  ND    …
10 FTNS European, U.S.A. Familial      …
11 MHA/SBS European, U.S.A. Familial      …
12 FTNS Iraqi Jewish, Israel Familial      Toren et al. 1999
13 FTNS European, U.S.A. Familial      Peterson et al. 1985
14 FTNS European, Italy Familial      Rocca et al. 1993
15 APSM European, U.S.A. Familial  ND    …
16 EPS European, U.S.A. Familial      Epstein et al. 1972
17 APSM European, U.S.A. Sporadic  ND    …
18 FTNS African American, U.S.A. Sporadic      Moxey-Mims et al. 1999
19 APSM European, U.S.A. Sporadic  ND    …
20 APSM European, U.K. Sporadic      …
21 FTNS European, Italy Familial      Velasco et al. 2000
22 EPS European, U.S.A. Familial      Epstein et al. 1972
23 FTNS European, Belgium Familial      …
24 EPS European, Belgium Familial      Nurden and Nurden 1996
25 FTNS European, Belgium Familial      …
26 MHA/SBS European, Australia Familial      …
27 FTNS Chinese, Australia Familial      Colville et al. 2000
NOTE.—ND p no data available.
a Diagnoses of MHA and SBS that were not confirmed by electron microscopy and thus were not differentiated from one another are designated as “MHA/SBS.”
b  p present;  p absent.
c Additional clinical histories are provided in the stated references.
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Figure 1 Schematic representation of MYH9 genomic structure (not drawn to scale) and the spectrum of mutations identified in the
MYH9 gene. The 40 coding exons and the promoter (noncoding exon A) are represented by vertical colored bars. Intron A (Int A) contains
enhancer elements. Mutations shown above the genomic structure have been identified in this cohort or in our previous study (May-Hegglin/
Fechtner Syndrome Consortium 2000, indicated by a superscript “1”). Mutations shown below the genomic structure have been reported by
other groups (Kelly et al. 2000 [“2”]; Kunishima et al. 2001 [“3”]; Lalwani et al. 2000 [“4”]). Clinical disorders are color-coded as shown in
the key. Red mutations indicate the purely hematological disorders. Within this group, individuals with MHA are labeled in red, those with
SBS are in red and underlined, and those in whom a diagnosis of MHA or SBS could not been differentiated are marked with an asterisk (*).
Tris pH 8.8, 50 mM KCl, 1.5 mM MgCl2, and 0.8 U
of AmpliTaq GOLD DNA polymerase (Perkin Elmer).
PCR cycle conditions included an initial denaturation
of 95C for 10 min, followed by 40 cycles of 95C for
1 min, 53C–61C (table 3) for 1 min, 72C for 1 min,
and a final 5-min extension at 72C. Amplification of
the promoter (see fig. 1) required 5% dimethyl sulf-
oxide, whereas the exon 31–32 amplimer required 0.4
mM dNTP and an extension time of 2.5 min.
Mutation screening was performed using the Trans-
genomic Wave denaturing high-performance liquid chro-
matography (DHPLC) system (Transgenomic). All am-
plicons were analyzed at two melting temperatures (ta-
ble 3). Detected heteroduplexes were subsequently se-
quenced. PCR samples for sequencing were purified (Qia-
gen) and were sequenced in both directions using ABI
BigDye terminator sequencing (Applied Biosystems) on
an ABI 3700 DNA Sequencer. Data were analyzed using
ABI Sequencing Analysis 3.3 (Applied Biosystems) and
Sequencher 3.11 (Gene Codes Corp.) software programs.
DNA sequencing of two independent amplification
products confirmed mutations. To rule out polymor-
phisms, genomic DNA isolated from 94 unrelated con-
trol subjects were screened for the presence of the iden-
tified mutations, using DHPLC followed by sequencing
if any heteroduplex pattern was observed.
Haplotype Analysis
Haplotype analysis was performed to determine the
ancestry of certain identified mutations. Four microsat-
ellite markers from the Marshfield Medical Research
Foundation and three novel dinucleotide markers,
D22S1745, D22S1746, and D22S1747, were analyzed
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Table 3
Oligonucleotide Sequences, PCR Annealing Temperature, and DHPLC Conditions for Each MYH9 Amplicon
MYH9
AMPLICONa
OLIGONUCLEOTIDE SEQUENCE (5′r3′) AMPLIMER
SIZE
(bp)
ANNEALING
TEMPERATURE
(C)
DHPLC CONDITIONS
(starting–final %
of solution B
[temperature in C])b
Sense Antisense 1 2
Prom CAG TGG GTG TAG CAG GAA GG GCG ATG AAG GTG CCA ACT A 395 61 59–65 (68) 59–65 (69)
Enh CTT AGC CTC CCT GAG CCT CT CAA AGC CAA AGG GAA ACT CA 211 55 54–60 (61) 54–60 (62)
Ex1 TCC TTC TCC TCC CCG CTT AG TCC TTC AAG CCC CCT TCT CA 500 55 59–65 (63) 60–66 (61)
Ex2 CAT CAG GGA GTG CCT TCA CA ATC ACC AGC CAC TAG ATC AA 400 55 60–66 (57) 60–66 (58)
Ex3 CAT CTG TGA CAC TGT GCT CC GGT TTC AGT AGG AGA CCT CAA G 210 55 54–60 (58) 54–60 (59)
Ex4 ACA CGT TGG GTC CTT CAC G GTG CTC TTC CTC CAT CAT CCC 284 57 58–64 (62) 58–64 (63)
Ex5 AAA CCT CTG TTC CTG GCA CG ATA GCA CCG AGT CTG AAC CG 340 55 57–63 (62) 57–63 (64)
Ex6 TGG CCT GGT ACA TGG GTC AGT GCT GGA ATC AGG AGG CA 302 55 58–64 (59) 58–64 (58)
Ex7 CAT GCC ACT GCA CTC CAA C TCT TCA GGT GCT CTC CAG C 290 55 55–63 (57)c 55–63 (58)c
Ex8 ACG TCA CTG GCT ACT CTG CG CCA CAC TCG ACC ATA GGA GG 320 55 58–64 (61) 58–64 (62)
Ex9 TGG CTT GAG GTG CCT CTG AT ATT TCC GCA AGA CCT TCC CTC 270 52 55–61 (62) 55–61 (61)
Ex10 TTG CTC ATT CAC CCC GTG G CCT CAA CTG TGC TGC TGC A 329 55 54–60 (62) 57–63 (59)
Ex11 TTA CTG GGG CAT AGG GTA TGA GG GGA TAA GGC AAC CAA CAG GC 287 55 56–62 (61) 56–62 (63)
Ex12 TGG GTG GAT AAA GGG AAG GC AAC CAA CAC AGA GCT GAG GT 430 55 59–65 (61) 59–65 (62)
Ex13 TCT GTG GGA TTC AGG GGA TT ACT GGG TGA GTC ATT GTG CA 420 55 55–61 (62) 55–61 (63)
Ex14 CTT AGG GGT GGA AAT GCT GGA ACT GTG GAG GTG GGA AGA TGA 324 55 55–61 (60) 55–61 (62)
Ex15 GGT CCT GTT GTT TCA TTC TGT CTC C GAG AAA CGA CTG AAG GCT CTG TG 445 55 60–66 (62) 60–66 (63)
Ex16 GTT CCC TGA CTA TTC TCC GAC TG CAC CTC TGG GAC TCA CTG CA 256 55 53–59 (65) 53–59 (66)
Ex17 CCT TGT CTC ATT CAG CCG AAG A GCA TCC ACC GAC CAC TGA T 362 55 56–62 (61) 58–64 (57)
Ex18 CCT TCC CAG CAT CCT GTT G GAA CTG CCC GAT TCT ACT CCT C 697 55 61–67 (62) 63–69 (60)
Ex19 AGC TTG AGG ACA AGA CCA GG AGC CAG GTA TGT ATG GTG GTG 254 55 56–62 (62) 56–62 (63)
Ex20 TTC CAG CCG AGC ATG TCT CT CCT GGA CTG AGC CTG CAC TG 210 55 56–62 (61) 56–62 (63)
Ex21 GGC TCT CCA GAT GAA AGC TAC TT AAA GGG AAC ACC TCT CAC TG 496 55 59–65 (62) 59–65 (63)
Ex22 TGG GCT CAC AGA CCT TGC TA CAG AAG AGA CAG GAA GCA GC 370 55 59–65 (64) 59–65 (65)
Ex23 GTA CCT CGC TGT TTC AGG GG AGT GCT GTA GTG TGA CCC AG 450 55 61–67 (59) 61–67 (58)
Ex24 GAG ACA GAA CCC ATG GCA CT AGT GCC GAG AAC TAG GGC CAG 305 55 57–63 (64) 57–63 (65)
Ex25 TGT CCT GCA AAC TCT GCT CC TCC ATG TCT CCA AGC CAA GG 350 55 54–60 (62) 54–60 (61)
Ex26 GAA AAG CTG CCT GGA GTG CC CAG GAC TGG TTT GGA TTC TG 341 55 56–64 (63)c 56–64 (62)c
Ex27 GGG TCC AGT GAT GAT AGA CC CAG AGA GCA CAC ATG CAC CT 370 55 61–67 (61) 58–64 (63)
Ex28 TTG TGA CTC AGG TCC AGC TTT TGC GTG GAC ACA GAG GCC T 260 55 55–61 (63) 55–61 (64)
Ex29 CTA AAT CAG CAG GAC CAG CT CCT TGA GAG CAC TGA TGT GGG 416 55 58–64 (64) 60–66 (62)
Ex30 (GGC)3TGA GCA GGT GCC ATC TCG G
d TCA ACA AGC CAG AGC CTG AG 454 59 54–60 (65) 54–60 (66)
Ex31 TCC CCA GGG AGC TTA GGC CCG ACC CTC TGT GAT GAC CC 361 59 58–64 (63) 58–64 (62)
Ex32 CCT GAC TTG GGC TCT CTG GG AGA GAA CAG AAG CCT GCG TG 309 55 57–63 (63) 59–65 (64)
Ex31/32 TCC CCA GGG AGC TTA GGC ACC CCG AGA CAG GAG GCT A 805 55 63–69 (62) 63–69 (63)
Ex33 CTG AGT TCA GAG CTA GGG CA TGT AGT TGG CTC AGT CGG GT 290 55 56–62 (63) 56–62 (62)
Ex34 GCA TTG AGT GGA GCA CCA GC GGA GCC CCG CTA TGA AAC GG 412 55 60–66 (62) 60–66 (61)
Ex35/36 GGG AAG GAT GGT CTT GTG GG AGG CCA GCT CTG CCG TGG TG 420 55 60–66 (63) 60–66 (64)
Ex37 CCC AAG GGT TTG GTG GGA TC CTG GTT GTG GCC CAG ATT TG 403 55 60–66 (62) 60–66 (61)
Ex38 CCG GAC CCT CTG AAG GAG G CCC TGC CTG TCA CCC CAT CT 229 52 55–61 (64) 55–61 (65)
Ex39 AGA TGG GGT GAC AGG CAG GG GCC AGA AGG GGC AGG GAT TG 401 59 60–66 (62) 60–66 (63)
Ex40 GAG TGG TCC TGT CTA GCT CAG GGA GGC TGT GGT GTC TGT CT 346 57 57–63 (62) 55–61 (64)
a Prom p promoter; Enh p enhancer; Ex p exon.
b Solution B consists of 0.1 M triethylammonium acetate (TEAA) and 25% acetonitrile. Time length of gradient was 3 min, unless otherwise specified.
c Time length of gradient was 4 min.
d (GGC)3 indicates a GC clamp (GGCGGCGGC) placed at the 5
′ end of the primer.
(fig. 2). Novel markers were generated. Tandem repeats
flanking theMYH9 gene were identified using the Tandem
Repeats Finder program (Benson 1999; Tandem Repeats
Finder Web site). The sense and antisense primers (5′r3′),
respectively, of the new dinucleotide markers are as
follows: D22S1745, CACACACATTTTCTTCATCCAC
and CTGGATGAAGTTGGACACC; D22S1746, TTCC-
CACAGAACCATTCC and CTACTTGAGAATGAGC-
CACC; and D22S1747, CCTGGAGAGGTCTGAGT-
ATT and GGTCAGGATAAACAGTGGAG. Markers
were amplified by PCR in multiplexes, on the basis of
their expected sizes and fluorescent end-labels, and then
were electrophoretically separated on a 4.2% denaturing
polyacrylamide gel, on an ABI 377 DNA Sequencer. Data
were analyzed using the ABI Genescan 3.11 and Geno-
typer 2.5 (Applied Biosystems) software packages. Hap-
lotypes were then determined according to the pedigrees.
Molecular Modeling
The globular-head mutations were modeled onto the
X-ray crystallographic structure of the chick smooth-
muscle myosin motor domain (Dominguez et al. 1998),
obtained from the Protein Data Bank of the Research
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Figure 2 A, Chromosome location of MYH9 and of the microsatellite markers used in the haplotype analysis. Drawing is not to scale.
Physical distances are indicated. Heterozygosity (Htz) values for each marker are shown, as determined from the Marshfield Medical Research
Foundation human genetic map or by the amplification of DNA from 95 healthy white control individuals (data not shown). B, Haplotype
analysis of markers flanking the MYH9 locus in three E1841K carriers. Shared haplotype is indicated in boldface, and genotypes where phase
was determined are underlined. M p E1841K mutation. Individual A was reported in our previous study as “individual 3” (May-Hegglin/
Fechtner Syndrome Consortium 2000).
Collaboratory for Structural Bioinformatics (ID 1BR2).
The atomic coordinates of this structure served as a tem-
plate for the identified human MYHIIA mutations. All
of the amino acids and potentially interacting residues
in the chick smooth-muscle myosin were conserved and
were identical with respect to the human MYHIIA se-
quence (fig. 3), and they are numbered according to this
sequence. All in silico substitutions for the mutations,
as well as model building, were calculated and rendered
with the computer software suites QUANTA, INSIGHT
II (Molecular Simulations), or O (Jones et al. 1991), for
molecular visualization. Since no detailed high-resolu-
tion structural information is available for the coiled-
coil domain, mutations in this region were modeled us-
ing helical wheel diagrams (Schiffer and Edmundson
1967).
Results
Spectrum of MYH9 Mutations
The 40 MYH9 coding exons (exons 1–40), the pro-
moter found in exon A, and a 120-bp region of intron
A containing enhancer elements (fig. 1) were screened
in 27 individuals with a diagnosis of MHA ( ), SBSnp 4
( ), FTNS ( ), EPS ( ), or APSM (np 3 np 13 np 3 np
), using DHPLC followed by DNA sequencing.4
MYH9 mutations were identified for the first time in
EPS (R702C) and APSM (R702C, R705H, and S1114P).
In total, MYH9 mutations were identified in 20 affected
individuals (table 4). The location of the mutations is
represented schematically in figure 1. Eight different sin-
gle-nucleotide substitutions were identified, including
three that were previously undescribed: 1119GrC
(K371N) in exon 10, 2105GrA (R702H) in exon 16,
and 3340TrC (S1114P) in exon 25 (table 4). Three of
the eight mutations were located in the globular head,
whereas the remaining five were present in the coiled-
coil domain (table 4; fig. 1). Four mutations were fre-
quently observed in this cohort: R702C in exon 16,
D1424N in exon 30, E1841K in exon 38, and R1933X
in exon 40. The missense mutation R702C was identified
in individuals diagnosed with FTNS, EPS, and APSM,
whereas the D1424N, E1841K, and R1933X mutations
were found in individuals with FTNS, MHA, and SBS
(fig. 1).
Several lines of evidence indicated that these muta-
tions were pathological. First, where family members
were available, each mutation cosegregated with the re-
spective phenotype. In cases in which the mutation was
not present in either parent, it was therefore consistent
with a de novo mutation. Second, each of the sequence
changes was absent in 94 unaffected, unrelated control
individuals. Finally, amino acid sequence-alignment
analysis of 15 smooth-muscle and nonmuscle myosins
(Sellers 1999, 2000) revealed conservation of the sub-
stituted residues (fig. 3) (May-Hegglin/Fechtner Syn-
drome Consortium 2000).
Evolutionary History of Mutations
To investigate the possible evolution of the mutations,
haplotype analysis was performed on the region flanking
the MYH9 locus, using seven microsatellite markers.
Four markers previously used for the localization of the
gene were used (Martignetti et al. 2000): D22S1142,
D22S1173, D22S283, and D22S272 (fig. 2). Three novel
markers, D22S1745, D22S1746, and D22S1747 (Ge-
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Figure 3 Clustal W alignment of the human MYHIIA amino acid sequence with the amino acid sequences of nonmuscle and smooth-
muscle myosins, using the BLASTP program from NCBI. The predicted affected amino acids for the identified missense mutations are shown
in boxes. Conserved amino acid changes at the positions of the mutated residues are underlined. Abbreviations and GenBank accession numbers
are as follows: Hs MYHIIA, Homo sapiens MYHIIA (accession number P35579); Rn MYHA, Rattus norvegicus nonmuscle myosin heavy
chain A (accession number AAA74950); Rn neur MHC, R. norvegicus neuronal myosin heavy chain (accession number S21801); Gg MYHIIA,
Gallus gallus MYHIIA (accession number AAA48974); Xl MYHIIA, Xenopus laevis MYHIIA (accession number AAC83556); Hs MYHIIB,
H. sapiens MYHIIB (accession number AAA99177); Rn MYHB, R. norvegicus nonmuscle myosin heavy chain B (accession number AAF61445);
Bt MYHB, Bos taurus MYHB (accession number BAA36494); Gg MYHIIB, G. gallus MYHIIB (accession number AAA48988); Xl MYHB,
X. laevis MYHIIB (accession number AAA49915); Gg SMMHC, G. gallus SMMHC (accession number P10587); Oc SM2,Oryctolagus cuniculus
smooth-muscle myosin 2 (accession number P35748); Mm SM2, Mus musculus SM2 (accession number JC5421); Dm NMII, Drosophila
melanogaster nonmuscle myosin heavy chain II (accession number AAB09049); and Ce NMYII, Caenorhabditis elegans nonmuscle myosin
heavy chain II (accession number AAA83339).
nome Database), were generated against tandem repeat
sequences in close proximity to the MYH9 locus (fig. 2).
D22S1745 and D22S1746 lie ∼4.2 kb and ∼9.1 kb cen-
tromeric (3′) to the MYH9 gene, respectively, and
D22S1747 is positioned ∼3.9 kb telomeric (5′) to the
MYH9 gene (fig. 2). Genomic DNA from 1100 white
individuals was amplified for each marker. The hetero-
zygosity values for these novel markers were .36, .58,
and .46, respectively, and the number of observed alleles
was 6, 13, and 6, respectively (see the Genome Database
Web site). Using these seven markers, haplotypes were
determined for seven R702C carriers, two families with
D1424N, and three E1841K carriers (two families and
one individual) from this cohort (table 4) and our pre-
vious study (May-Hegglin/Fechtner Syndrome Consor-
tium 2000). Phase was determined, where possible, in
two families with the D1424N mutation (FTNS indi-
viduals 9 and 23) and in two E1841K carriers: individual
21 (with FTNS) in this cohort and one individual (with
MHA/SBS) from our previous study (May-Hegglin/
Fechtner Syndrome Consortium 2000). The phase was
indeterminable in the third E1841K carrier (individual
14), and a possible disease haplotype was constructed
from the alleles present at each genotype. A common
haplotype was demonstrated for three E1841K carriers
(fig 2). No common haplotype was demonstrated for the
R702C or D1424N carriers (data not shown).
Molecular Modeling
The MYHIIA globular-head mutations K371N and
R702H, first described in this cohort, as well as the
R705H mutation identified in nonsyndromic deafness,
DFNA17 (Lalwani et al. 2000), were modeled on the
X-ray crystallographic structure of chick smooth-muscle
myosin (fig. 4) (Dominguez et al. 1998). Each of the
specific residues is invariant within known nonmuscle
myosins and the chick smooth-muscle myosin heavy
chain (SMMHC) (fig. 3).
The R702H and R705H mutations lie within or ad-
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Table 4
MYH9 Mutations Identified in the Cohort of 27 Individuals with a Diagnosis of MHA, FTNS, SBS, EPS, or APSM, as Indicated
Patient ID
Numbera Disorder
Ethnic Origin and
Country of Origin Exon
Nucleotide Substitution
(Codon Change)
Protein
Alteration
MYHIIA
Domain
1 SBS European, Germany 30 4270GrA (GACrAAC) D1424N Coiled coil
2 SBS European, Germany 30 4270GrA (GACrAAC) D1424N Coiled coil
3 FTNS European, Germany 16 2104CrT (CGTrTGT) R702C Globular head
5 MHA/SBS European, Germany 10 1119GrC (AAGrAAC) K371Nb Globular head
8 MHA European, U.S.A. 30 4270GrA (GACrAAC) D1424N Coiled coil
9 FTNS European, U.S.A. 30 4270GrA (GACrAAC) D1424N Coiled coil
10 FTNS European, U.S.A. 30 4270GrC (GACrCAC) D1424H Coiled coil
13 FTNS European, U.S.A. 30 4270GrA (GACrAAC) D1424N Coiled coil
14 FTNS European, Italy 38 5521GrA (GAGrAAG) E1841K Coiled coil
15 APMS European, U.S.A. 16 2105GrA (CGTrCAT) R702Hb Globular head
16 EPS European, U.S.A. 16 2104CrT (CGTrTGT) R702C Globular head
17 APSM European, U.S.A. 25 3340TrC (TCTrCCT) S1114Pb Coiled coil
18 FTNS African American, U.S.A. 16 2104CrT (CGTrTGT) R702C Globular head
19 APSM European, U.S.A. 16 2104CrT (CGTrTGT) R702C Globular head
20 APSM European, U.K. 16 2104CrT (CGTrTGT) R702C Globular head
21 FTNS European, Spain 38 5521GrA (GAGrAAG) E1841K Coiled coil
22 EPS European, U.S.A. 16 2104CrT (CGTrTGT) R702C Globular head
23 FTNS European, U.S.A. 30 4270GrA (GACrAAC) D1424N Coiled coil
26 MHA/SBS European, Australia 40 5797CrT (CGArTGA) R1933X Coiled coil
27 FTNS Chinese, Australia 40 5797CrT (CGArTGA) R1933X Coiled coil
a Patient IDs are the same as those listed in table 2.
b Previously undescribed mutation.
jacent to the “SH1-SH2” helix of the globular-head do-
main, proximal to the highly reactive “SH1” cysteine
that is responsible for the power transduction state. On
the basis of predictions from the wild-type chick
SMMHC crystallographic structure, the d-guanido
groups of the two wild-type arginines supply positive
charge density within the overall negatively charged cleft
(fig. 4b). The introduction of a histidine residue at po-
sition 702 (fig. 4a and 4c) would reduce the positive
charge density. The wild-type arginine at position 705
can form potential stabilizing interactions with either
L89 or A87 (fig. 4d). The mutation to H705 disrupts
the potential bonding pattern, preventing these stabiliz-
ing interactions (fig. 4e).
K371 resides in the middle of an a-helix (fig. 4f). The
potentially reactive e-amino group of the wild-type lysine
residue is oriented perpendicular to the axis of the helix,
facing towards the solvent and completely exposed, with
no apparent interactions with other portions of the pro-
tein (fig. 4f). The K371N mutation results in the poten-
tial creation of a bond between the amide nitrogen of
the asparagine and the carbonyl oxygen of the T367
residue at the n-4 position in the a-helix (fig. 4g). Thus,
this mutation could result in the abnormal stabilization
of the region.
Helical wheel representations (Schiffer and Edmund-
son 1967) were used to assess the possible altered in-
teractions resulting from the S1114P and D1424N mu-
tations in the coiled-coil domain (data not shown).
Although the serine residue is only conserved in the my-
osin IIA subclass, a change to proline would be expected
to have a major effect on the a-helical secondary struc-
ture, since it is a classical a-helix “breaker” and thus
could alter coiled-coil interactions. The other amino ac-
ids found at this position within the myosin family are
compatible with the maintenance of an a-helical con-
formation. Most notably, the conserved a-helical do-
main, ∼1,100 amino acids in length, contains no other
prolines. The D1424N mutation involves the change to
the amide form of the wild-type residue. Although there
is no drastic change in the side group conformation, a
loss of a potentially favorable coulombic interaction oc-
curs in a structurally critical position, as suggested by
conservation of this residue (May-Hegglin/Fechtner Syn-
drome Consortium 2000) (fig. 3).
Discussion
In the present study, the spectrum of MYH9 mutations
and the genotype-phenotype relationship in 27 individ-
uals diagnosed with MHA, SBS, FTNS, and two FTNS-
like disorders—EPS and APSM—were investigated. The
combination of previously identified mutations, MYH9
mutations reported here, and haplotype data indicates
that MHA, SBS, FTNS, APSM, and EPS represent a class
of allelic disorders with variable phenotypic diversity.
This spectrum of disorders is collectively being termed
“MYHIIA syndrome.”
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Figure 4 A space-filling representation of the wild-type chick smooth-muscle myosin (b) compared with the mutated residues R702H (a)
and R705H (c); This 4.5-A˚ radial sphere was derived from the X-ray crystallographic structure (Dominguez et al. 1998), as described in the
Subjects and Methods section. d, Possible interactions of wild type. e, Ablation of these interactions in the R705H mutation. f, Alpha helical
conformation of wild type. g, Potential stabilization of mutation K371N.
Mutation Analysis
Eight different mutations in the MYH9 gene were
identified in this new group of affected families, includ-
ing three that were previously undescribed: K371N,
R702H, and S1114P. The R702C mutation, previously
identified in patients with FTNS, has now also been iden-
tified in patients with EPS and APSM, suggesting that
MYH9 mutations can also be the cause of these two
disorders. Moreover, the clinical phenotype of FTNS,
APSM, and EPS, as well as our genetic data, suggest that
all three conditions are, in fact, the same disease entity.
Our data reveal the presence of frequent mutations
within this spectrum of clinically and morphologically
distinguishable macrothrombocytopenias. This is more
apparent when our data are combined with all reported
mutations (fig. 1; Kelley et al. 2000; May-Hegglin/Fecht-
ner Syndrome Consortium 2000; Kunishima et al.
2001). The mutation-detection rate for MYHIIA syn-
drome was 74% (20/27). If each phenotypic variation
is taken into consideration, the mutation-detection rates
were as follows: MHA/SBS, 71% (5/7); FTNS (including
APSM), 76% (13/17); and EPS, 67% (2/3).
Genotype-Phenotype Correlations
The clinical phenotype of individuals sharing the same
mutation can be variable, as is demonstrated by indi-
viduals with the D1424N, E1841K, and R1933X mu-
tations. First, the D1424N mutation in exon 30, pre-
viously described in only one patient with MHA
(Kunishima et al. 2001), was detected in an additional
patient with MHA (individual 8), and now in individuals
with FTNS (individuals 9, 13, and 23) and SBS (indi-
viduals 1 and 2). Second, the E1841K mutation in exon
38, previously described in patients with MHA and
MHA/SBS (Kelley et al. 2000; May-Hegglin/Fechtner
Syndrome Consortium 2000), has now been found in
two patients with FTNS, individuals 14 and 21. Third,
the exon 40 missense mutation, R1933X, previously
found in a large Italian family with MHA and originally
used for linkage of this trait (Martignetti et al. 2000;
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May-Hegglin/Fechtner Syndrome Consortium 2000),
has now been identified in an additional seven patients
with MHA: individual 26 of the present study, four in-
dividuals reported by Kelley et al. (2000), and two in-
dividuals reported by Kunishima et al. (2001), as well
as in a patient with FTNS (individual 27 of the present
study). Thus, all three mutations have been found in
patients with FTNS and MHA/SBS.
Finally, the R702C mutation in exon 16 has now been
shown to occur in a total of eight individuals with a
diagnosis of FTNS, EPS, or APSM. Since these three
disorders share the clinical features of macrothrombo-
cytopenia, deafness, and nephritis, the genetics suggest
that all three disorders may be classified as one syndrome
with mild phenotypic variation, including the presence/
absence of presenile cataracts. Moreover, a different mu-
tation at the same codon, R702H, was identified in in-
dividual 15, who was also diagnosed with APSM. In
marked contrast, no mutations have been found in this
codon in the purely hematological disorders, MHA and
SBS ( ). Therefore, substitutions at codon 702 arenp 7
consistently associated with the manifestation of ne-
phritis and deafness in addition to macrothrombocy-
topenia, indicating that the preservation of codon 702
is critical for the maintenance of MYHIIA function in
these affected organs.
A different mutation located in the same region,
R705H, was recently identified in a family with non-
syndromic deafness, DFNA17 (Lalwani et al. 2000). In-
terestingly no platelet abnormalities, leukocyte inclu-
sions, nephritis, or cataracts were observed in any of the
family members (Lalwani et al. 2000). Thus, the mu-
tations in these two codons, R702C, R702H, and
R705H, appear to define a common region associated
with the pathogenesis of deafness, whereas codon 702
seems specifically involved in the molecular pathology
of macrothrombocytopenia and nephritis.
Structure-Function Relationships
Previously, six MYHIIA mutations (May-Hegglin/
Fechtner Syndrome Consortium 2000) with structure-
function correlates were revealed, according to struc-
tural data derived from the molecular modeling of the
chick smooth-muscle X-ray crystallographic structure
(Dominguez et al. 1998) for the N-terminal globular-
head mutations and from helical wheel analysis for the
carboxy-terminal coiled-domain a-helical mutations.
The R702C mutation occurs in the “SH1-SH2” helix
that links the interface of the converter domain with the
amino terminus of the myosin head. There are two
highly reactive cysteine residues at either end of this
“SH1-SH2” helix, C694 and C704, which are critical
to the conformational changes of the globular-head do-
main accompanying specific states of power transduc-
tion in the myosin-ATPase system (Harrington and
Rodgers 1984). Additionally, this region has been im-
plicated in the “swinging lever arm” hypothesis to ex-
plain the structural basis of motility (reviewed by Hou-
dusse and Sweeney [2001]).
Two additional mutations lying in this region of
MYHIIA—R702H (individual 15) and R705H (Lalwani
et al. 2000)—were analyzed. The R702H and R705H
mutations share several common structural features.
Both residues are present in a-helices of the “SH1-SH2”
region (Dominguez et al. 1998) and involve the altera-
tion of basic amino acid residues, which are among the
most energetically favorable and stabilizing side chains
in a-helices. Judging from amino acid substitutions on
a well-characterized synthetic peptide that forms an a-
helical polypeptide (O’Neil and DeGrado 1990), the mu-
tations to histidine at both the R702 and R705 positions
would result in an energy difference of 0.62 kcal/mole
in the a-helix, thus destabilizing the secondary structure.
Myosin cross-linking studies have biochemically con-
firmed these potential interactions and the close prox-
imity of the residues within the domain depicted in figure
4a and c (Lu and Wong 1989). Lastly, modifications in
the region of the two cysteines defining the functionality
of this helical region have been shown to have severe
biochemical ramifications, by altering nucleotide ex-
change, ATPase activity, and actin sliding activity (Tie-
pold et al. 2000). In addition to the destabilizing forces
of the RrH mutations within this helical region, the
R705H mutation involves the disruption of potential
bonds with A87 or L90, resulting in a lower propensity
for stability of this secondary structure motif (fig. 4e).
The S1114P mutation present in individual 17 is ex-
pected to result in a highly unstable protein. Energy cal-
culations using a synthetic peptide show that the re-
placement of a serine with a proline greatly destabilizes
the helix, by 12.65 kcal/mol (O’Neil and DeGrado
1990). It is interesting to note that, in accord with the
structural constraints imposed by proline, no proline res-
idues are present in the wild-type MYHIIA coiled-coil
domain. This ∼1,100–amino acid sequence stretches
from the end of the head domain (P836) to within 33
amino acids of the carboxy terminus (P1927, P1931,
and P1958).
Unexpectedly, and in contrast to the aforementioned
changes, the previously undescribed globular-head mu-
tation K371N in individual 5 (fig. 4g) results in an ap-
parent stabilization of the region, by the creation of a
bond between the amide nitrogen of the asparagine with
the carbonyl oxygen of the T367 residue at the n-4 po-
sition in this exposed surface a-helix.
Three of the five missense mutations present in the
coiled-coil domain, D1424H, E1841K, and R1933X,
were described in the first study (May-Hegglin/Fechtner
Syndrome Consortium 2000). These coiled-coil domain
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mutations cannot be directly modeled onto homologous
structures that are solved to atomic resolution by current
structural biological approaches. The common D1424N
mutation resides in a region of the a-helical coiled coil,
producing a higher-ordered left-handed superhelix. This
is an energetically feasible way of stabilizing the long
helix at the carboxy terminus. Electrostatic interactions
of residues surrounding the hydrophobic interface of the
coiled coils provide further stabilization of the chains.
Although the change of an aspartic acid to its corre-
sponding nonionizable amide asparagine is a relatively
conservative alteration, with respect to the possible in-
teracting surface areas and three-dimensional space-fill-
ing conformation, the examination of this mutation
through use of a helical wheel diagram indicates a po-
tential destabilizing effect. A net change in the charge
density (1 to 0) may destabilize the interaction, with
concomitant deleterious effects upon the normal protein
dimerization and assembly in that portion of the a-hel-
ical coiled coil.
Haplotype Analysis
The haplotype analysis indicated a common haplotype
at a minimal distance of 2.3 Mb surrounding the MYH9
locus (D221746 to D22S272) in the three E1841K car-
riers. Similar analyses suggested multiple origins of
the R702C and D1424N mutations. One of the three
E1841K carriers had a clinical diagnosis of MHA/SBS
(May-Hegglin/Fechtner Syndrome Consortium 2000),
whereas two had FTNS (individuals 14 and 21). These
two individuals had nephritis and deafness, although
only individual 14 had cataracts. Further clinical and
historical investigation of the family with MHA/SBS
confirmed the absence of nephritis, deafness, and ocular
abnormalities. The allele frequencies of the four markers
that form the shared haplotype were determined in a
white control population or were taken from the CEPH
database. Given the frequency of the shared alleles, the
probability of three unrelated individuals sharing this
haplotype was calculated to be !1 in . Therefore,62# 10
these three families may share a common ancestor. Thus,
it is hypothesized that MHA/SBS and FTNS are phe-
notypic variations of a single syndrome. This could ex-
plain why intrafamilial phenotypic variation occurs in
these disorders, as observed by us and others (Peterson
et al. 1985; Rocca et al. 1993).
Conclusion
Mutations were not identified in all affected individ-
uals (7/27). The absence of a mutation may be explained
both at the clinical and molecular level. Macrothrom-
bocytopenia is a genetically heterogeneous disorder
(Mhawech and Saleem 2000). In addition, there is a
normal distribution of platelet size, ranging from very
small to giant (Bain 1985). The combination of ma-
crothrombocytopenia, leukocyte inclusions, and the ad-
ditional phenotypic features of nephritis, deafness, and
cataracts are unique to FTNS, EPS (no cataracts), or
APSM and thus are more “readily diagnosed” as a single
syndrome entity. MHA and SBS are diagnosed on the
basis of the presence of macrothrombocytopenia and
Do¨hle-like bodies, as well as from the pattern of inher-
itance. Do¨hle-like bodies are generally visible only if a
blood smear is stained with May-Gru¨nwald Giemsa
stain in a time-dependent manner (Greinacher et al.
1990a, 1992). Ultrastructural features of these inclu-
sions are only detectable by electron microscopy, and
this preparation is also time sensitive. Thus, the diag-
nosis may either be missed or incorrectly applied,
depending on the availability of appropriate testing
facilities.
At the molecular level, a mutation in MYH9 may not
have been identified for different reasons. First, because
of technical limitations: DHPLC has been shown to be
a highly sensitive mutation-detection technique (Choy et
al. 1999), but, as with any screening strategy, mutations
may still be missed. Second, the mutation may be present
outside the analyzed regions—for example, in a non-
coding region that may have a regulatory function.
Third, the mutation may be a deletion or duplication
on the order of a single exon, which would be undetected
by DHPLC and DNA sequencing, or the mutation could
be a major deletion or duplication that would only be
detected by northern or Southern analysis. Finally, since
MYH9 mutations were identified in 74% of individuals,
genetic heterogeneity cannot be excluded. Mutations
may be present in the associated myosin light chains, in
another nonmuscle myosin, or in a protein that forms
complexes with MYHIIA.
In summary, MYH9 mutations in patients with EPS
and APSM, as well as additional MYH9 mutations in
patients with MHA, FTNS, and SBS, have been identi-
fied. These mutations occurred in conserved positions
and critical regions in both the globular-head and the
coiled-coil domains of MYHIIA and are therefore pre-
dicted to result in altered assembly, dimerization, or sta-
bility of the quaternary myosin complex. Whether the
molecular pathogenesis of these disorders arises from a
dominant-negative effect caused by the formation of
normal-defective myosin dimers or by haploinsufficiency
is currently under investigation. The causes of the phe-
notypic variation also remain to be delineated. For
example, a gene-modifier effect (reviewed by Nadeau
[2001]) could be present. A second possibility is the in-
volvement of a regulatory factor that affects the differ-
ential expression of MYH9 in the affected tissues. Al-
together, the molecular and clinical data indicate that
these six disorders—MHA, SBS, FTNS, EPS, APSM, and
DFNA17—represent variants of a single syndrome,
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MYHIIA syndrome, with a broad phenotypic spectrum
ranging from a lack of symptoms, mild bleeding ten-
dencies, or high-tone sensorineural deafness to severe
macrothrombocytopenia with deafness, presenile cata-
racts, and nephritis, resulting in end-stage renal failure.
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